In a private share issue placement in June Vaccibody raised 733.000 € from existing owners. The funding will be allocated to the company’s development of VB10.16, a therapeutic vaccine against cervical cancer.
During the last 6 months Vaccibody has obtained significant progression with conclusive data in animal models on superior therapeutic effect of VB 10.16 and in April Vaccibody partnered with Cobra Biologicals for the GMP production of VB 10.16 (Read more: http://www.outsourcing-pharma.com/Contract-Manufacturing/Cobra-Confident…)
“This funding will take us through the planned GLP safety and toxicity studies, allowing us to commence our first-in-man study with VB 10.16 in 2014. It is indeed exciting times for Vaccibody.” CEO Ole Henrik Brekke, says in a comment.